George Joulwan - Emergent Biosolutions Independent Director
| EBS Stock | USD 7.27 0.06 0.83% |
Director
Gen. George A. Joulwan, USA is Independent Director of the Company. Gen. Joulwan distinguished military career spans 36 years from 1961 to his retirement as a fourstar general and the Supreme Allied Commander of NATO in 1997. In 1998 General Joulwan founded, and currently serves as president of, One Team, Inc., which provides business consulting services. Previously, General Joulwan served as a director of General Dynamics Corporation from 1998 through 2012, and currently serves on several private company and charitable boards. He was a professor at the United States Military Academy at West Point and served on the Board of Trustees for the United States Military Academy. General Joulwan was a professor of National Security Strategy at the National Defense University. General Joulwan is a graduate of West Point and holds a Master degree in Political Science and an Honorary Doctor of Law degree from Loyola University in Chicago. As a retired U.S. Army general, we believe General Joulwan brings a unique perspective to our board. Through his extensive and distinguished military career, he has developed critical leadership and management skills that we believe make him a significant contributor to our board. In addition, we believe General Joulwan foreign policy experience and knowledge of the government and the military provide valuable insight into international defense markets and the global defense industry. since 2013.
| Age | 80 |
| Tenure | 12 years |
| Address | 400 Professional Drive, Gaithersburg, MD, United States, 20879 |
| Phone | 240 631 3200 |
| Web | https://www.emergentbiosolutions.com |
Emergent Biosolutions Management Efficiency
The company has Return on Asset of (0.0422) % which means that on every $100 spent on assets, it lost $0.0422. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.3464) %, meaning that it generated no profit with money invested by stockholders. Emergent Biosolutions' management efficiency ratios could be used to measure how well Emergent Biosolutions manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.66 in 2025. Return On Capital Employed is likely to gain to -0.68 in 2025. At this time, Emergent Biosolutions' Non Currrent Assets Other are comparatively stable compared to the past year. Other Assets is likely to gain to about 231 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 799.2 M in 2025.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Linda Rhodes | Zoetis Inc | 70 | |
| Philip CFA | Prestige Brand Holdings | N/A | |
| Willie Reed | Zoetis Inc | 65 | |
| Sanjay Khosla | Zoetis Inc | 68 | |
| Richard Schutter | Bausch Health Companies | 79 | |
| Gregory Norden | Zoetis Inc | 62 | |
| Antoinette Leatherberry | Zoetis Inc | 58 | |
| Gary Costley | Prestige Brand Holdings | 55 | |
| Andrew Eschenbach | Bausch Health Companies | 78 | |
| Frank DAmelio | Zoetis Inc | 63 | |
| Dawn Zier | Prestige Brand Holdings | 55 | |
| Russel Robertson | Bausch Health Companies | 72 | |
| Katharyn Field | Akanda Corp | 41 | |
| Robert Scully | Zoetis Inc | 71 | |
| Robert Power | Bausch Health Companies | 63 | |
| Sheila Hopkins | Prestige Brand Holdings | 64 | |
| Sarah Kavanagh | Bausch Health Companies | 63 | |
| Paul Bisaro | Zoetis Inc | 59 | |
| Argeris Karabelas | Bausch Health Companies | 66 | |
| James Jenness | Prestige Brand Holdings | 73 | |
| William Steere | Zoetis Inc | 83 | |
Management Performance
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.0422 |
Emergent Biosolutions Leadership Team
Elected by the shareholders, the Emergent Biosolutions' board of directors comprises two types of representatives: Emergent Biosolutions inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Emergent. The board's role is to monitor Emergent Biosolutions' management team and ensure that shareholders' interests are well served. Emergent Biosolutions' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Emergent Biosolutions' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kelly Warfield, Senior Development | ||
| Sean Kirk, Executive Vice President - Manufacturing and Technical Operations | ||
| William Hartzel, Senior Bioservices | ||
| Robert Burrows, IR Contact Officer | ||
| Stephanie Duatschek, Chief VP | ||
| Sue Bailey, Independent Director | ||
| Jerome Hauer, Independent Director | ||
| Haywood Miller, Interim Officer | ||
| Kathryn Zoon, Independent Director | ||
| Seamus Mulligan, Director | ||
| George Joulwan, Independent Director | ||
| Karen Smith, Executive Vice President Chief Medical Officer | ||
| Paul Williams, Senior Business | ||
| Keith Katkin, Independent Director | ||
| Simon MD, Chief Development | ||
| Jessica Perl, Corporate Counsel | ||
| Robert Kramer, CFO, Interim Executive Vice President - Corporate Services Division, Principal Financial and Accounting Officer, Treasurer | ||
| Richard MBA, CFO VP | ||
| Jennifer Fox, Executive Vice President - External Affairs, General Counsel, Corporate Secretary | ||
| Katherine Strei, Executive Vice President - Human Resources and Communications, Chief Human Resources Officer | ||
| Michelle Pepin, Senior Officer | ||
| Fuad ElHibri, Executive Chairman of the Board | ||
| Coleen Glessner, Executive Compliance | ||
| Lynn Kieffer, VP Communications | ||
| Joseph Papa, CEO President | ||
| Marvin White, Director | ||
| Atul Saran, Executive Vice President Corporate Development, General Counsel and Corporate Secretary | ||
| Robert Sr, Pres CEO | ||
| Adam Havey, Executive VP and President of Biodefense Division | ||
| Louis Sullivan, Independent Director | ||
| Ronald Richard, Lead Independent Director | ||
| Zsolt Harsanyi, Non-Executive Independent Chairman of the Board | ||
| Richard Lindahl, Chief Financial Officer, Executive Vice President, Treasurer |
Emergent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Emergent Biosolutions a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.0422 | ||||
| Profit Margin | (0.19) % | ||||
| Operating Margin | 0.25 % | ||||
| Current Valuation | 903.37 M | ||||
| Shares Outstanding | 54.18 M | ||||
| Shares Owned By Insiders | 2.15 % | ||||
| Shares Owned By Institutions | 57.78 % | ||||
| Number Of Shares Shorted | 6.95 M | ||||
| Price To Earning | 1.67 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Emergent Stock Analysis
When running Emergent Biosolutions' price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.